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IN THE LAST 2 years, there have been sev-
eral reports of the administration of heter-
ologous antilymphocyte globulin (ALG) to 
humans. The objectives have varied. In our 
own institutionl -4 and more recently in sev-
eral others5-9 ALG prepared from immune 
horse serum has been added to the basic 
immunosuppressive regimen of azathio-
prine and prednisone after the transplanta-
tion of vital whole organs including the 
kidney, liver, and heart. In addition, het-
erologous antilymphocyte derivitives have 
been used alone for the purpose of deter-
mining what changes in immunologic re-
activity were thereby induced in volun-
teers,10 or in an effort to treat autoimmune 
diseases8 and lymphatic leukemia.H 
There is no point in reviewing here the 
large body of incontrovertible evidence that 
ALG can slow or prevent the rejection of a 
variety of homografts in several species of 
lower animals as well as in subhuman pri-
mates. Suffice it to say that ALG also has an 
easily demonstrable immunosuppressive ef-
fect when used as the only treatment in 
man inasmuch as skin graft survival is pro-
longed10 and the expression of pre-existing 
hypersensitivity states is blunted or elimi-
nated.2,5,8,12 
Equally unchallenged is the fact that 
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there is a significant morbidity with the 
clinical administration of ALG as most fully 
described by Kashiwagi13 and mentioned by 
others as well.5,6,10 The intramuscular injec-
tions are almost always painful, often cause 
fever, may eventually evoke classical for-
eign protein reactions including anaphy-
laxis, and can precipitate thrombocytopenic 
crises. However, lethal complications must 
be rare. We have treated more than 100 
recipients of renal or liver homografts with 
ALG without a drug-related death. 
Conceding that the immunosuppressive 
effect of immune globulin is not doubted 
in any species including man in which it 
has been tested, other avenues of inquiry 
remain open including whether the benefit 
of ALG is outweighed by its side effects, 
if there is really a need to add globulin 
therapy to that with the standard drugs or 
if this practice will lead to increased sur-
vival, how the globulin might be refined 
and made less toxic, and what improved 
schedules of administration could be 
evolved for clinical use. It is upon these 
issues that this communication will touch. 
THE QUESTION OF NEED 
Transplantation from Related Donors. A 
trial of ALG therapy was begun at the Uni-
versity of Colorado in June 1966 because of 
dissatisfaction with the results obtained us-
ing azathioprine and prednisone together in 
the preceding 4 years. During that time, the 
mortality during the first 12 postoperative 
months after intrafamilial renal homotrans-
plantation had remained almost fixed at 
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about 30% despite the acquisition of exten-
sive experience, adjustments in the way in 
which azathioprine and prednisone were 
administered, the use of ancillary measures 
such as local homograft irradiation, and 
even the application of histocompatibility 
matching. 
The events leading to death or loss of the 
homograft in the significant minority of pa-
tients were relatively predictable. In an 
individual case, it soon became evident that 
continuing function of the transplanted kid-
ney was dependent upon toxic doses of 
prednisone. If these were lowered, it usually 
became necessary to remove the organ and 
return the patient to chronic dialysis. If the 
doses were not reduced, the homograft 
could be saved but often at the cost of a 
lethal infection. In such unfavorable cases, 
the pattern leading to eventual failure was 
almost always identifiable within the first 
few postoperative months although some 
of these unfavored patients lived on for long 
periods as semi-invalids. 
The way in which a one to 4 month course 
of ALe, added as an adjuvant to the basic 
azathioprine-steroid regimen, appeared to 
have influenced the outlook of subsequently 
treated recipients of consanguineous homo-
grafts has been reported on several occa-
sions1'3 and will only be briefly summarized 
now. In comparison to our previous experi-
ence, the quantities of both azathioprine 
and especially prednisone were reduced, 
the overall quality of homograft function 
was better maintained, and the mortality 
was decreased. Eighty-five consecutive in-
trafamilial renal transplantations have been 
performed with several variations of ALe 
therapy, often with poor donor-recipient 
histocompatibility as determined by Tera-
saki. 
All but 8 of the recipients are still alive, 
including 19 of the first 20 who received 
their kidneys from 21 to 27 months ago; 44 
of the survivors have been followed for a 
year or more. Four of the deaths were due 
to non-renal medica] complications: mas-
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sive pulmonary embolization E1U~f months), 
reticulum cell sarcoma ( 6 months), 
granulomatous colitis EP~f months), and 
acute yellow atrophy (25 days) which was 
first diagnosed on the morning after opera-
tion. The other 4 failures resulted from 
technical misadventures which either led to 
an immediate or delayed fatality (after 2 
to 127 days). It should be noted that 2 of 
the 8 deaths were in a small subgroup of 13 
patients to be separately discussed later who 
were treated with a specially prepared pure 
equine gamma e globulin that had appar-
ently lost most of its immunosuppressive 
potency in the course of refinement. 
In the total group, there were 3 examples 
in 2 patients of hyperacute rejection 
(Shwartzman reaction) of the initial trans-
plants14; the homografts were removed 
promptly and replaced with functioning 
kidneys a few weeks later. There were no 
other retransplantations either early or late. 
None of the patients has been returned to 
a chronic dialysis program, and only one 
of the survivors is currently threatened with 
loss of his homograft. The exceptional pa-
tient was one who was treated with the 
highly refined globulin. 
More will not be said about these sta-
tistics. Few groups could realize more com-
pletely than our own that long term patient 
and kidney survival can often be obtained 
with or without ALe treatment. It is only 
necessary to recall that 31 (67.4%) of our 
first 46 recipients of related homo grafts 
treated from 1962 to early 1964 (15) lived 
for at least one year and that 28 (61%) are 
still alive 4~f to almost 6 years after opera-
tion; only one of these patients has required 
late retransplantation. 
In our hands, these results could not be 
significantly improved upon until the ad-
vent of ALe therapy. If in contrast, as has 
been said (but not yet well documented), 
other groups using standard azathioprine-
steroid therapy have satisfactorily lowered 
their kidney loss rate and mortality without 
imposing stringent histocompatibility cri-
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teria for the selection of candidates, there is 
little need in those institutions to consider 
the use of ALe or any other modification 
of treatment. The decision about the ade-
quacy of the immunosuppression is a local 
one. 
Transplantation from Cadaveric Donors. 
We have not had sufficient experience to 
suggest what effect, if any, ALe will have 
on the long term results after cadaveric 
renal transplantation since we have accu-
mulated only 12 such cases in the last 2 
years; 8 of the recipients are still alive, one 
in an anephric state. One of the patients 
destroyed 2 consecutively placed kidneys 
with Shwartzman reactions and died in 54 
days. Two others, who had received organs 
from a common donor, died within a one 
day interval of massive pulmonary emboli 
P~f months after operation. The 2 latter 
homografts had functioned well. At autopsy, 
there were no histologic signs of active re-
jection and little or no evidence of healed 
past rejection.s 
The other 9 patients received their kid-
neys 4 to 22 months ago, the first 4 more 
than a year ago from donors with whom 
there were extremely poor histocompatibil-
ity (Terasaki) matches. Two of the 4 oldest 
homo grafts failed after one year and had to 
be removed; both of the recipients were 
returned to the chronic dialysis program 
where one committed suicide 6 months later 
by water ingestion. The 2 other recipients 
with the longest followup still have life sus-
taining but subnormal renal function after 
14 and 16 months. Their creatinine clear-
ances are 20 and 40 mIl minute. 
The donors for the more recently treated 
5 surviving patients were selected by Tera-
saki with prospective histocompatibility typ-
ing; a mismatch in a major HLA antigen 
group was present in only one case. These 
recipients all still have good renal function 
but the followup is only 4 to 10 months 
(average 6 months). 
In spite of the small number of observa-
tions, some tentative conclusions might be 
justified. It was possible in all the 11 fore-
going transplantations in which initial urine 
excretion was obtained to easily control re-
jection during the period of ALe therapy; 
in fact overt rejection was diagnosed during 
this interval in only 4 instances. However, 
with the discontinuance of ALe in all the 
recipients of histoincompatible kidneys, 
slow but progressive deterioration of the 
homo grafts was soon detectable. The situa-
tion was in marked contrast to that after 
intrafamilial transplantation where emer-
gence from the 4 month level of convales-
cence with good renal function proved to 
be a highly reliable sign of a favorable long 
term prognosis. The fate of histocompatible 
non-related kidneys under these conditions 
of therapy can only be speculated upon 
until longer followups are available. 
PURIFICATION AND POTENCY Loss 
In Kashiwagi's toxicity report,13 it was 
stressed that the precipitin response of the 
treated patients was principally directed 
against the alpha and beta globulins in the 
ammonium sulfate precipitated ALe and 
that, in turn, there was a correlation be-
tween the level to which the precipitin titers 
rose and the likelihood of an anaphylactic 
reaction; high titers were common after sev-
eral months of injections. In contrast, anti-
bodies against the horse gamma e globulin 
were not usually detectable. Consequently, 
it was hoped that the incidence and severity 
of the side reactions might be reduced by 
the administration of pure gamma e globu-
lin (hereafter called ALee) which was 
prepared in bulk quantities with a DEAE 
batch technique.16 The refined product was 
given Patients 58 through 70 in the intra-
familial ALe series. The ALee batches had 
leukoagglutinin titers of 1:2,000-8,000 and 
protein concentrations of 1.9-3.5 gm%. The 
intramuscular doses were 4 to 8 ml depend-
ing upon the antiwhite cell titers. 
Measurable precipitating antibodies 
against the ALee developed in only one of 
the 13 patients. Although minor toxic mani-
festations were seen with about the same 
frequency as with the previously used ALG, 
there were no anaphylactic reactions. Un-
fortunately, it soon became apparent that 
the immunosuppressive effect of the pro-
duct had been largely lost. All of the pa-
tients had satisfactory post-transplantation 
diureses. However, 7 of the 13 then devel-
oped severe rejection crises from ~ to 14 
days later. Prednisone doses were increased 
in 2 cases to as much as 400 mg per day. 
Five of the recipients had secondary eleva-
tions of the BUN to more than 150 mg%. 
In 4 cases, resumption of hemodialysis was 
necessary for 1, O~I 4, and 5 weeks before 
adequate urine excretion resumed. Two of 
the 13 patients eventually died, although 
not from renal failure. Nevertheless, the 
high dose steroid therapy required for many 
postoperative weeks was a contributing fac-
tor to the unfavorable outcome. 
The difficulties in this small group of pa-
tients can be appreciated by a comparison 
with the other 72 consanguineous recipients 
who received ammonium sulfate precipi-
tated ALG, 58 before and 14 after the 
ALGG trial. Only 3 of the patients treated 
with ALG after technically satisfactory 
operations had rejections severe enough to 
cause secondary azotemia greater than 150 
mg%, and there was only one instance 
where interim postoperative support (2 
dialyses) with the artificial kidney became 
necessary because of uncontrolled rejection. 
A plausible explanation of the apparent 
loss of ALG potency in these cases and in 
the recently reported dog experiments of 
Clunie et alP may be related to the wider 
distribution of antiwhite cell antibodies in 
horse ALS as compared to that raised in 
the rabbit. The leukoagglutinins in the lat-
ter species are mostly in the easily separable 
gamma G globulins.18,19 Attention was 
drawn by both Iwasaki20 in our laboratories 
and Fateh-Moghadam21 to the fact that the 
leukoagglutinins of horse ALS were also 
found in the T-equine globulin fraction, 
which consists mostly of "fast" gamma G 
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and beta globulins; the potential practical 
importance of this finding was overlooked 
by most of the workers in the field. 
More recently, Kashiwagi and Townsend 
in our laboratory22 have re-examined the 
relative contribution of the different immu-
noglobulins to the total antilymphocyte ac-
tivity of equine ALS. The horse studied had 
received an intensive immunization with 
human splenic lymphocytes for 2 months. 
More than half of the antileukocyte anti-
body was in the T-equine globulin. This 
fraction was eliminated by the technique 
used in preparing the ALGG used for the 
clinical trial. Moreover, Kashiwagi and 
Townsend showed in companion canine ex-
periments, involving differential separation, 
that the discarded T-equine globulin had a 
lymphopenic effect at least as great as that 
caused by the highly refined "slow" gamma 
G globulin. Experiments with canine renal 
transplantation are underway to determine 
the relative immunosuppressive efficacy of 
the 2 fractions. 
ALTERNATIVE REGIMENS 
Two unsatisfactory aspects of the present 
methods of ALG use were mentioned ear-
lier. First, there has been an increased inci-
dence of classical foreign protein reactions 
with successive injections, particularly after 
several months. Second, evidence was cited 
that late rejection of cadaveric renal homo-
grafts often developed once the serum ther-
apy had been stopped in cases with poor 
histocompatibility matches; the same thing 
has been seen in recipients of livers.23 Ef-
forts have been made in recent months to 
deal with these problems. 
One approach has been to give double 
doses of ALG in the early post-transplan-
tation period with the objective of promot-
ing prompt tolerance, such as that which 
can be produced with ALS in rodents.24,25 
The last 14 adult recipients of renal homo-
grafts in the intrafamilial series described 
earlier were given daily doses of 8 ml of 
ammonium sulfate precipitated horse ALG 
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which had a leukoagglutinin titer of 1:8000, 
a cytotoxicity titer of 1:2000 to 1:4000 and 
a protein concentration of 4.3 to 5.2 gm%. 
Highly significant lymphopenia, a finding 
not previously observed with half these 
doses, was invariably seen. Thus far, only 2 
of the recipients have developed an un-
equivocal rejection. In these cases the pro-
cess was easily controlled by increasing the 
steroid doses. 
The use of these large quantities of ALG 
has usually led eventually to thrombocyto-
penia, severe enough in a few instances to 
require platelet transfusions. Otherwise, the 
treatment of this complication required only 
the temporary discontinuance of globulin 
therapy, which was then resumed each time 
the platelets returned toward normal. In 
these patients the initial lymphopenia oc-
curred without platelet depression, but 
within 2 or 3 weeks there was an almost 
invariable temporal correlation between the 
induced falls in the lymphocyte and throm-
bocyte counts. 
The batches of ALG used for the fore-
going patients had been absorbed with 
human thrombocytes16 and had very low to 
undetectable titers of antiplatelet antibod-
ies as measured by a standard thromboag-
glutination method. It is probable that the 
delayed thrombocytopenic effect was due 
to antibodies raised against antigenic de-
terminants which are shared by human 
platelets and lymphocytes. 
That this might be the case was suggested 
by Pichlmayr,8 who found a reduction in 
leukoagglutinin titers of his horse ALG 
after absorption with platelets from the 
species against which immunization was 
conducted. Kashiwagi and Townsend22 
were unable to confirm these findings. How-
ever, they provided support for the concept 
of cross reactivity by showing that throm-
boagglutinin and leukoagglutinin titers in 
raw horse antidog ALS were both reduced 
by absorption with washed canine lympho-
cytes. Whatever the explanation for the 
thrombocytopenia. its appearance has im-
posed the most important practical limita-
tion we have encountered on the doses of 
ALG that can be given to humans. 
An alternative and possibly safer ap-
proach than that of high dose "blitzkrieg" 
therapy would be to extend the chronicity 
of heterologous globulin treatment. Prob-
ably this could often be achieved without 
any special measures since ALG was 
stopped in the majority of our patients only 
because an arbitrary 4 month period had 
passed and not because of the appearance 
of toxicity. Moreover, even with the de-
velopment of immunity to horse globulin, 
desensitization by standard techniques may 
be feasible as has been shown in 2 of our 
patients. 
Another solution could be the secondary 
use of ALG from another species. A transi-
tion from horse to rabbit ALG has already 
been made in 2 of our liver recipients. 
Whereas administration of the equine 
globulin caused fever and intense local re-
actions, the rabbit protein proved to be 
non-toxic. Reserve supplies of ALS are also 
being raised in our laboratory in the goat 
and cow. 
SUMMARY 
Heterologous ALG has been used in more 
than 100 human recipients of renal or hep-
atic homografts. There has been consider-
able consequent morbidity but no fatal toxic 
reactions. The results with both kinds of 
transplantation have been better than could 
previously be achieved in our institutions. 
Two significant problems of ALG therapy 
have been emphasized in this report. First, 
rejection has been frequently observed after 
transplantation from non-related donors fol-
lowing the discontinuance of ALG treat-
ment, indicating the need to test other ways 
of using this agent than that now being 
employed. Suggestions have been made 
about how therapy might be made more ef-
fective including switching from one heter-
ologous donor species to another, or the ad-
ministration of an intensified early course 
of ALe in an effort to promote tolerance. 
Second, a serious loss of potency has evi-
dently resulted from attempts to highly 
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purify the gamma e globulin from horse 
ALS, necessitating a return at least tempo-
rarily to the crude ALe obtained by am-
monium sulfate precipitation. 
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